Trial Profile

A Phase 2 study of adagrasib in combination with chemo-immunotherapy for patients with TPS < 50%

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adagrasib (Primary) ; Antineoplastics (Primary) ; Immunotherapies (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms KRYSTAL 17; KRYSTAL-17

11 Aug 2023 New trial record
08 Aug 2023 According to a Mirati Therapeutics media release, the company intends to provide an update on this study and outline potential registrational development plans in 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com